小非编码 RNA 和胰腺导管腺癌:将诊断、发病机制、耐药性和治疗潜力联系起来。
Small non-coding RNAs and pancreatic ductal adenocarcinoma: Linking diagnosis, pathogenesis, drug resistance, and therapeutic potential.
发表日期:2024 Jul 08
作者:
Ryan N Fuller, Ann Morcos, Joab Galvan Bustillos, David Caba Molina, Nathan R Wall
来源:
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
摘要:
这篇综述全面研究了小非编码 RNA (sncRNA) 和胰腺导管腺癌 (PDAC) 之间复杂的相互作用,这是一种治疗选择有限的毁灭性恶性肿瘤。我们的分析揭示了 sncRNA 在 PDAC 生物学各个方面的关键作用,包括诊断、发病机制、耐药性和治疗策略。 sncRNA 已成为 PDAC 有前途的生物标志物,在患病组织中表现出独特的表达谱。 sncRNA 差异表达模式通常可在体液中检测到,具有早期和微创诊断方法的潜力。此外,sncRNA 在 PDAC 发病机制中表现出复杂的参与,调节关键的细胞过程,如增殖、凋亡和转移。此外,对 sncRNA 介导的致病途径的机制见解阐明了新的治疗靶点和干预措施。本综述的一个重点是致力于揭示 PDAC 耐药性背后的 sncRNA 机制。在分子水平上了解这些机制对于制定克服耐药性的策略至关重要。在探索治疗前景时,我们讨论了 sncRNA 本身作为治疗剂的潜力,因为它们以高特异性调节基因表达的能力使它们成为靶向治疗的有吸引力的候选者。总之,这篇综述整合了 PDAC 中 sncRNA 的最新知识,提供了对其诊断、致病和治疗相关性的整体视角。通过阐明 sncRNA 在 PDAC 生物学中的作用,这篇综述为开发新型诊断工具和靶向治疗方法提供了宝贵的见解,这对于改善 PDAC 患者的预后至关重要。版权所有 © 2024。由 Elsevier B.V 出版。
This review comprehensively investigates the intricate interplay between small non-coding RNAs (sncRNAs) and pancreatic ductal adenocarcinoma (PDAC), a devastating malignancy with limited therapeutic options. Our analysis reveals the pivotal roles of sncRNAs in various facets of PDAC biology, spanning diagnosis, pathogenesis, drug resistance, and therapeutic strategies. sncRNAs have emerged as promising biomarkers for PDAC, demonstrating distinct expression profiles in diseased tissues. sncRNA differential expression patterns, often detectable in bodily fluids, hold potential for early and minimally invasive diagnostic approaches. Furthermore, sncRNAs exhibit intricate involvement in PDAC pathogenesis, regulating critical cellular processes such as proliferation, apoptosis, and metastasis. Additionally, mechanistic insights into sncRNA-mediated pathogenic pathways illuminate novel therapeutic targets and interventions. A significant focus of this review is dedicated to unraveling sncRNA mechanisms underlying drug resistance in PDAC. Understanding these mechanisms at the molecular level is imperative for devising strategies to overcome drug resistance. Exploring the therapeutic landscape, we discuss the potential of sncRNAs as therapeutic agents themselves as their ability to modulate gene expression with high specificity renders them attractive candidates for targeted therapy. In summary, this review integrates current knowledge on sncRNAs in PDAC, offering a holistic perspective on their diagnostic, pathogenic, and therapeutic relevance. By elucidating the roles of sncRNAs in PDAC biology, this review provides valuable insights for the development of novel diagnostic tools and targeted therapeutic approaches, crucial for improving the prognosis of PDAC patients.Copyright © 2024. Published by Elsevier B.V.